Cargando…

Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures

OBJECTIVES: Anti-osteoporotic drugs (AOD) are essential for secondary prevention of osteoporotic fracture (OF) in patients with established osteoporosis. However, data about AOD utilization rates are scarce among patients with OF. This study was therefore aimed at determining the AOD utilization rat...

Descripción completa

Detalles Bibliográficos
Autores principales: Aypak, Cenk, Bircan, Mustafa A., Özdemir, Ayşe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rambam Health Care Campus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345764/
https://www.ncbi.nlm.nih.gov/pubmed/35701156
http://dx.doi.org/10.5041/RMMJ.10473
_version_ 1784761502851399680
author Aypak, Cenk
Bircan, Mustafa A.
Özdemir, Ayşe
author_facet Aypak, Cenk
Bircan, Mustafa A.
Özdemir, Ayşe
author_sort Aypak, Cenk
collection PubMed
description OBJECTIVES: Anti-osteoporotic drugs (AOD) are essential for secondary prevention of osteoporotic fracture (OF) in patients with established osteoporosis. However, data about AOD utilization rates are scarce among patients with OF. This study was therefore aimed at determining the AOD utilization rates among those particularly vulnerable patients. MATERIALS AND METHODS: This cross-sectional study followed the medical records of patients with OF starting from their first OF diagnosis date. Each patient’s preventive osteoporosis treatments (vitamin D, calcium+vitamin D) and AOD utilization rate were recorded for a 12-month period following OF diagnosis. RESULTS: A total of 210 patients (168 females, mean age: 67.8±11.9 years; 42 males, mean age 62.4±16.1 years) were enrolled in the study. Of these, 65.7% (n=138) did not use any medication for primary protection against osteoporosis before OF diagnosis. The ratio of patients not using any type of medication for secondary prevention after OF increased from 26.5% to 51% during a 12-month period. In addition, by one year following diagnosis, AOD usage rate had decreased from 62.3% to 41.3%. CONCLUSION: The AOD usage rates for secondary prevention of OF were insufficient, and cessation rates were high. Identification of factors associated with decreased AOD utility rates will provide important information for guiding patient follow-up in order to reduce the occurrence of OF.
format Online
Article
Text
id pubmed-9345764
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Rambam Health Care Campus
record_format MEDLINE/PubMed
spelling pubmed-93457642022-08-11 Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures Aypak, Cenk Bircan, Mustafa A. Özdemir, Ayşe Rambam Maimonides Med J Original Research OBJECTIVES: Anti-osteoporotic drugs (AOD) are essential for secondary prevention of osteoporotic fracture (OF) in patients with established osteoporosis. However, data about AOD utilization rates are scarce among patients with OF. This study was therefore aimed at determining the AOD utilization rates among those particularly vulnerable patients. MATERIALS AND METHODS: This cross-sectional study followed the medical records of patients with OF starting from their first OF diagnosis date. Each patient’s preventive osteoporosis treatments (vitamin D, calcium+vitamin D) and AOD utilization rate were recorded for a 12-month period following OF diagnosis. RESULTS: A total of 210 patients (168 females, mean age: 67.8±11.9 years; 42 males, mean age 62.4±16.1 years) were enrolled in the study. Of these, 65.7% (n=138) did not use any medication for primary protection against osteoporosis before OF diagnosis. The ratio of patients not using any type of medication for secondary prevention after OF increased from 26.5% to 51% during a 12-month period. In addition, by one year following diagnosis, AOD usage rate had decreased from 62.3% to 41.3%. CONCLUSION: The AOD usage rates for secondary prevention of OF were insufficient, and cessation rates were high. Identification of factors associated with decreased AOD utility rates will provide important information for guiding patient follow-up in order to reduce the occurrence of OF. Rambam Health Care Campus 2022-07-31 /pmc/articles/PMC9345764/ /pubmed/35701156 http://dx.doi.org/10.5041/RMMJ.10473 Text en Copyright: © 2022 Aypak et al https://creativecommons.org/licenses/by/3.0/This is an open-access article. All its content, except where otherwise noted, is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0 (https://creativecommons.org/licenses/by/3.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Aypak, Cenk
Bircan, Mustafa A.
Özdemir, Ayşe
Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures
title Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures
title_full Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures
title_fullStr Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures
title_full_unstemmed Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures
title_short Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures
title_sort anti-osteoporotic drug utilization rates for secondary prevention among patients with osteoporotic fractures
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345764/
https://www.ncbi.nlm.nih.gov/pubmed/35701156
http://dx.doi.org/10.5041/RMMJ.10473
work_keys_str_mv AT aypakcenk antiosteoporoticdrugutilizationratesforsecondarypreventionamongpatientswithosteoporoticfractures
AT bircanmustafaa antiosteoporoticdrugutilizationratesforsecondarypreventionamongpatientswithosteoporoticfractures
AT ozdemirayse antiosteoporoticdrugutilizationratesforsecondarypreventionamongpatientswithosteoporoticfractures